OrthoPediatrics Corp.

DB:2X7 Stock Report

Market Cap: €521.5m

OrthoPediatrics Management

Management criteria checks 2/4

OrthoPediatrics' CEO is David Bailey, appointed in Jun 2020, has a tenure of 4.5 years. total yearly compensation is $2.72M, comprised of 18.4% salary and 81.6% bonuses, including company stock and options. directly owns 0.95% of the company’s shares, worth €4.95M. The average tenure of the management team and the board of directors is 4.2 years and 12.9 years respectively.

Key information

David Bailey

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage18.4%
CEO tenure4.5yrs
CEO ownership0.9%
Management average tenure4.2yrs
Board average tenure12.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Bailey's remuneration changed compared to OrthoPediatrics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$28m

Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$22m

Dec 31 2023US$3mUS$500k

-US$21m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

US$976k

Mar 31 2023n/an/a

US$4m

Dec 31 2022US$1mUS$415k

US$1m

Sep 30 2022n/an/a

US$9m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$906kUS$371k

-US$16m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$33m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$898kUS$371k

-US$33m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$15m

Dec 31 2019US$836kUS$300k

-US$13m

Sep 30 2019n/an/a

-US$11m

Jun 30 2019n/an/a

-US$10m

Mar 31 2019n/an/a

-US$10m

Dec 31 2018US$590kUS$266k

-US$12m

Sep 30 2018n/an/a

-US$25m

Jun 30 2018n/an/a

-US$26m

Mar 31 2018n/an/a

-US$26m

Dec 31 2017US$483kUS$258k

-US$24m

Compensation vs Market: David's total compensation ($USD2.72M) is above average for companies of similar size in the German market ($USD1.03M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Bailey (45 yo)

4.5yrs

Tenure

US$2,721,840

Compensation

Mr. David R. Bailey serves as the Chief Executive Officer at OrthoPediatrics Corp. since June 01, 2021. He serves as the President at OrthoPediatrics Corp. since June 3, 2020 and serves as its Director sin...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Throdahl
Executive Chairman15.9yrsno data0.75%
€ 3.9m
David Bailey
President4.5yrsUS$2.72m0.95%
€ 4.9m
Fred Hite
CFO, Principal Financial & Accounting Officer9.8yrsUS$2.04m0.62%
€ 3.3m
Daniel Gerritzen
Executive VP of Legal15.9yrsUS$1.35m0.32%
€ 1.7m
Gregory Odle
President of Scoliosisno dataUS$1.35m0.48%
€ 2.5m
Kevin Unger
President of Enabling Technologies1.6yrsUS$22.50kno data
Joseph Hauser
President of Trauma & Deformity Correction3.9yrsUS$1.35m0.37%
€ 2.0m
Mark Karshner
Senior Vice President of International Sales8.9yrsno datano data
Ray Garrison
Senior Vice President of Quality & Regulatory and Clinical2.9yrsno datano data

4.2yrs

Average Tenure

54yo

Average Age

Experienced Management: 2X7's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Throdahl
Executive Chairman15.9yrsno data0.75%
€ 3.9m
David Bailey
President3.1yrsUS$2.72m0.95%
€ 4.9m
Fred Hite
CFO, Principal Financial & Accounting Officer9.3yrsUS$2.04m0.62%
€ 3.3m
Terry Schlotterback
Lead Independent Director15.9yrsUS$185.00k0.086%
€ 447.2k
Peter Armstrong
Chair of Surgeon Advisory Boardno datano datano data
David Pelizzon
Director13.9yrsUS$180.00k0.10%
€ 528.7k
Bryan Hughes
Independent Director12.9yrsUS$190.00k0.053%
€ 276.3k
Henry Chambers
Member of Surgeon Advisory Boardno datano datano data
J. Gordon
Member of Surgeon Advisory Boardno datano datano data
H. Graham
Member of Surgeon Advisory Boardno datano datano data
Daniel Hoernschemeyer
Member of Surgeon Advisory Boardno datano datano data
Marie Infante
Independent Director10.9yrsUS$185.00k0.047%
€ 244.8k

12.9yrs

Average Tenure

68yo

Average Age

Experienced Board: 2X7's board of directors are seasoned and experienced ( 12.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 17:29
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OrthoPediatrics Corp. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
David TurkalyJMP Securities
Jonathan BraatzKansas City Capital Associates